Chlamydia pneumoniae and atherosclerosis: Current state and future prospectives

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 9-14

  Sessa, R ^a   Nicoletti, M ^b   Di Pietro, M ^a   Schiavoni, G ^a   Santino, Iolanda ^a   Zagaglia, C ^a   Del Piano, M ^a   Cipriani, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherosclerosis; C. pneumoniae; Diagnosis

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL DNA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

AORTA ATHEROSCLEROSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATTRIBUTABLE RISK; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; MACROPHAGE FUNCTION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SEROEPIDEMIOLOGY; SYSTEMIC DISEASE; VASCULAR ENDOTHELIUM;

EID: 62649083251     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200102     Document Type: Editorial

References (22)

1. Siscovick DS, Schwartz SM, Caps M, Wang SP, Grayston JT. Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology. J Infect Dis 2000; 181:S417-20.
2. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 2002; 15:1-20.
3. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 1998; 177:1322-5.
4. Yamaguchi H, Haranaga S, Widen R, Friedman H, Yamamoto Y. Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages. Infect Immun 2002; 70:2392-8.
5. Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 2004; 72:1843-55.
6. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus A, Solbach W, Maass M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103:351-6.
7. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK, Valtonen V. Serological evidence of an association of novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; ii:983-6.
8. Sessa R, Di Pietro M, Santino I, del Piano M, Varveri A, Dagianti A, Penco M. Chlamydia pneumoniae infection and atherosclerotic coronary disease. Am Heart J 1999; 137:1116-9.
9. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci 2008; 114:509-531.
10. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays recommendations from the Center for Disease Control and Prevention (USA) and the Laboratory Center for Disease Control (Canada). Clin Infect Dis 2001; 33:492-503.
11. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82:158-61.
12. Cochrane M, Pospischil A, Walker P, Gibbs H, Timms P. Distribution of Chlamydia pneumoniae DNA in atherosclerotic carotid arteries: significance for sampling procedures. J Clin Microbiol 2003; 41: 1454-7.
13. Sessa R, Di Pietro M, Schiavoni G, et al. Detection of Chlamydia pneumoniae in atherosclerotic coronary arteries. Int J Immunopathol Pharmacol 2004; 17: 301-06.
14. Sessa R, Di Pietro M, Schiavoni G, et al. Chlamydia pneumoniae DNA in patients with symptomatic carotid atherosclerotic disease. J Vasc Surg 2003; 37: 1027-31.
15. Blasi F, Boman J, Esposito G, et al. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis 1999; 180:2074-6.
16. Prager M, Türel Z, Speidl WS, et al. Chlamydia pneumoniae in carotid artery atherosclerosis: a comparison of its presence in atherosclerotic plaque, healthy vessels, and circulating leukocytes from the same individuals. Stroke 2002; 33:2756-61.
17. Cochrane M, Pospischil A, Walker P, Gibbs H, Timms P. Discordant detection of Chlamydia pneumoniae in patients with carotid artery disease using polymerase chain reaction, immunofluorescence microscopy and serological methods. Pathology 2005; 37:69-75.
18. Sessa R, Di Pietro M, Schiavoni G, et al. Chlamydia pneumoniae in asymptomatic carotid atherosclerosis. Int J Immunopathol Pharmacol 2006; 19:111-8.
19. Sessa R, Di Pietro M, Schiavoni G, et al. Measurement of Chlamydia pneumoniae bacterial load in peripheral blood mononuclear cells may be helpful to assess the state of chlamydial infection in patients with carotid atherosclerotic disease. Atherosclerosis 2007; 195:224-30.
20. de Kruif MD, van Gorp EC, Keller TT, Ossewaarde JM, ten Cate H. Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc Res 2005; 65:317-27.
21. Kalayoglu MV, Libby P, Byme GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288:2724-31.
22. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease. A meta-analysis of randomized control trials. JAMA 2005; 293:2641-7.